A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

As Stat reports, the federal judge's ruling means patients will lose access to less-expensive versions of Eli Lilly's weight loss drug, as well as diabetes treatment Mounjaro, from compounding ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Eli Lilly is ... to cut prescription drug prices in the US to the level paid by other comparable countries. Shares in Eli ...

CEO resigns as Eli Lilly (LLY) dominates the weight loss drug market and compounders threaten the company's financial outlook ...

Drugmaker Eli Lilly ... a huge trend in weight loss drugs. And orforglipron looks like it could be a game-changer, driving even more growth for Lilly. Geoffrey Seiler has no position in any ...

2024 US FDA says Lilly's weight-loss drug shortage is resolved The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly's blockbuster weight loss and ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...